Milan

• A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab … Recruiting
  2023-503224-66-00 5 2023-10-31 Atrial Fibrillation
• A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate … Recruiting
  2023-503295-25-00 10 2023-10-31 Resectable biliary tract cancers
• 177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus Recruiting
  2022-502154-13-00 5 2023-10-27 Patients with well to moderately differentiated neuroendocrine tumors
• Phase 1/2 Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis Recruiting
  2022-502597-16-00 9 2023-10-27 Intermediate or High-risk Primary or Secondary Myelofibrosis
• Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting
  2023-503661-28-00 5 2023-10-26 Hidradenitis Suppurativa
• Neoadjuvant pembrolizumab in high-risk thyroid cancers (NEPENTHE) Recruiting
  2024-519129-38-00 4 2023-10-25 thyroid cancers
• The 3TR Molecular Pathobiology-Driven Precision Therapy in RA (3TR Precis-The-RA) study Recruiting
  2022-502021-18-00 6 2023-10-12 Rheumatoid Arthritis
• Adaptative, multicenter, randomized, double-blind, parallel-group, placebo controlled, clinical trial, on the efficacy and tolerability of d … Recruiting
  2024-511961-12-00 10 2023-10-12 Knee osteoarthritis
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons with Severe or Moderate … Recruiting
  2023-503906-35-00 9 2023-10-11 Severe or Moderate Hemophilia A with or without factor VIII inhibitors
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting
  2023-510541-25-00 1 2023-10-09 Relapsed/Refractory B-cell Malignancies
• A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) … Recruiting
  2022-502160-20-00 5 2023-10-02 Idiopathic Immune Complex Mediated Membranoproliferative Glomeruloneph
• Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting
  2022-501515-14-00 5 2023-09-29 Newly Diagnosed Multiple Myeloma (NDMM)
• Effects of combined diuretic therapy on exercise capacity, alveolar-capillary diffusion and maintenance of euvolemia in chronic congestive h … Recruiting
  2024-519565-21-01 5 2023-09-21 congestive heart failure
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat … Recruiting
  2022-502851-79-00 5 2023-09-20 Active Idiopathic Inflammatory Myopathy (IIM)
• A Dose Escalation and Expansion Study of BGB-16673 in Patients with B Cell Malignancies Recruiting
  2022-502157-33-00 7 2023-09-18 B-Cell Malignancies
• Circulating microRNAs to choose the IO strategy in PD-L1≥50% NSCLC patients: the Ark clinical trial Recruiting
  2022-502253-34-00 4 2023-09-11 non-small cell lung cancer
• MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient … Recruiting
  2022-501810-77-00 5 2023-09-01 Relapsed or Refractory Marginal Zone Lymphoma
• Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM) Recruiting
  2022-502732-39-00 10 2023-09-01 Previously treated non-ocular advanced melanoma
• A Phase 1 study of LOXO-435 in Locally Advanced or Metastatic Solid Tumors with FGFR3 Gene Alterations Recruiting
  2022-502755-59-00 1 2023-08-30 Locally Advanced or Metastatic Solid Tumors with FGFR3 Alterations
• A Study to Evaluate the Efficacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis (ELIXIR) Recruiting
  2024-513562-19-00 5 2023-08-30 End-Stage Kidney Disease
• A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or … Recruiting
  2022-501508-82-00 3 2023-08-23 Solid Tumors
• A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients … Recruiting
  2022-501822-39-00 9 2023-07-31 Glioblastoma
• First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl- … Recruiting
  2023-510431-11-00 4 2023-07-21 Chronic Lymphocytic Leukemia
• Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting
  2022-500587-35-01 5 2023-07-06 Stroke

Showing 1,033–1,056 of 2,361 trials